@article{John C. Wood_Tara Glynos_Alexis Thompson_Patricia Giardina_Paul Harmatz_Barinder P. Kang_Carole Paley_Thomas D. Coates_2011, place={Pavia, Italy}, title={Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial}, volume={96}, url={https://haematologica.org/article/view/6014}, DOI={10.3324/haematol.2010.032862}, abstractNote={The US04 trial was a multicenter, open-label, single arm trial of deferasirox monotherapy (30–40 mg/kg/day) for 18 months. Cardiac iron response was bimodal with improvements observed in patients with mild to moderate initial somatic iron stores; relationship of cardiac response to labile plasma iron is now presented. Labile plasma iron was measured at baseline, six months, and 12 months. In patients having a favorable cardiac response at 18 months, initial labile plasma iron was elevated in only 31% of patients at baseline and no patient at six or 12 months. Cardiac non-responders had elevated labile plasma iron in 50% of patients at baseline, 50% patients at six months, and 38% of patients at 12 months. Risk of abnormal labile plasma iron and cardiac response increased with initial liver iron concentration. Persistently increased labile plasma iron predicts cardiac non-response to deferasirox but labile plasma iron suppression does not guarantee favorable cardiac outcome. <em>Study registered at <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> (<a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00447694&amp;atom=%2Fhaematol%2F96%2F7%2F1055.atom">NCT00447694</a>).</em&gt;}, number={7}, journal={Haematologica}, author={John C. Wood and Tara Glynos and Alexis Thompson and Patricia Giardina and Paul Harmatz and Barinder P. Kang and Carole Paley and Thomas D. Coates}, year={2011}, month={Jun.}, pages={1055-1058} }